MetaCap

AgomAb Therapeutics NV (AGMB) vs Editas Medicine (EDIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $253.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%EDIT-9.89%
+114%+22%-71%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%EDIT-9.89%
+109%+19%-71%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus EDIT key metrics
MetricAGMBEDIT
Share price$5.45$1.64
Market cap$268.40M$253.12M
1-day change-3.02%-4.09%
YTD return—-20.00%
1-year return—-32.23%
5-year return—-94.93%
EPS (TTM)$-2.08$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$40.52M
Revenue growth (YoY)—+25.39%
Net income (latest FY)—$-160.06M
Operating margin—-394.89%
Net margin—-395.01%
52-week high$17.82$3.94
52-week low$5.39$1.63
Distance from 52-week high-69.42%-58.38%
Analyst consensusstrong_buybuy
Avg. price target upside+591.19%+271.95%
Average volume208.99K2.63M
Shares outstanding49.25M154.34M
Employees6287
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About Editas Medicine

EDIT stock →

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees

AGMB vs EDIT FAQ

Which is bigger, AgomAb Therapeutics NV or Editas Medicine?

AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $253.12M for Editas Medicine (EDIT).

Are AgomAb Therapeutics NV and Editas Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons